Aequus Announces Director Resignation

0 18

April 22, 2022 16:30 ET | Source: Aequus Pharmaceuticals

VANCOUVER, British Columbia, April 22, 2022 (GLOBE NEWSWIRE) — Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announces that Mr. Jason Flowerday has resigned from the Aequus Board of Directors.

Douglas Janzen, Aequus’ Chair & Chief Executive Officer, stated: “We are excited for Jason and his new business ventures. We wish him the best and want to thank him for all his support and input over the years he served on our board.”

About Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its sales and marketing efforts to include several commercial products in ophthalmology and transplant. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Aequus Investor Relations
Email: investors@aequuspharma.ca
Phone: 604-336-7906

 83 total views,  2 views today

Leave A Reply

Your email address will not be published.